menu-hamburger-svgrepo-com

Metformin cuts long Covid rates by 41%

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Metformin is an anti-inflammatory agent commonly used to lower blood sugar levels in people with diabetes. It is a widely available and affordable generic drug, taken by approximately 150 million people worldwide. The study suggests that metformin could serve as an affordable preventive measure for long Covid, potentially providing a treatment option for a condition that has been challenging to address effectively.

In addition to reducing long Covid rates, the study found that patients receiving metformin at the time of infection also had a 42% reduction in emergency room visits, hospitalisations, or death. This suggests that metformin could also be effective as an outpatient treatment for Covid-19.

The researchers behind the study believe that metformin could be an alternative treatment option to Pfizer's oral Covid-19 antiviral medication Paxlovid (nirmatrelvir + ritonavir). While Paxlovid is considered the standard of care, some individuals may be unable to take it due to potential cross-interactions with other medications. Therefore, the researchers advocate for updating treatment guidelines to include metformin as a potential treatment option for people with Covid-19, considering its widespread availability and low cost.

The Parsemus Foundation, a research funder involved in the trial, supports efforts to advance innovative and neglected medical research to improve human and animal health. They have funded rigorous clinical studies, including the COVID-OUT trial, to evaluate the effectiveness of existing medications in treating Covid-19.

 

READ THE ORIGINAL STUDY HERE

Welcome to Medical Academic​

Get the most out of Medical Academic by telling us your occupation. This helps us create more great content for you and the community.

idea

1000’s of Clinical and CPD content compiled by Key Opinion Leaders and our expert medical editors.

connection

Access to medical webinars and events

Group 193

Access medical journals from industry leaders and expert medical editorials.

Congratulations! Your account was successfully created.

Please check your email for an activation mail. Click the activation link to activate your account

Stay up to date

Search for anything across CPD, webinars and journals
idea

1000’s of Clinical and CPD content compiled by Key Opinion Leaders and our expert medical editors.

connection

Access to medical webinars and events

Group 193

Access medical journals from industry leaders and expert medical editorials.

Congratulations! You have successfully booked your seat.

All webinar details will be emailed to your email address.

Did you know, you can book future webinars with a single click if you register an account with Medical Academic.

Congratulations! Your account was successfully created.

Your webinar seat has been booked and all webinar details will be emailed to your registered email address

Why not register for Medical Academic while booking your seat for this webinar?

Future Medical Academic webinars can be booked with a single click, all with a Medical Academic account… and it’s FREE.

Book webinar & create your account

* (Required)

idea

1000’s of Clinical and CPD content compiled by Key Opinion Leaders and our expert medical editors.

connection

Access to medical webinars and events

Group 193

Access medical journals from industry leaders and expert medical editorials.

Congratulations! Your account was successfully created.

Thank you for registering. You can now log in to your account.

Create your account

* (Required)

Login with One Time Pin (OTP)

Enter your registered email address to receive an OTP

A verification code will be sent to your email address. Please ensure that admin@medicalacademic.co.za is on your safe sender list.

We've sent your OTP